ORAL PROGRAMME

Wednesday, October 19, 2016	
13:00–14:30	Registration | *Room: The Plaza Suite Foyer*
Room	
14:30–17:00	**Session 1: Genetic Factors, Cellular Pathways, and Neuronal Vulnerability** | *Room: The Ballroom* *Chair: John Hardy, UK*
14:30–15:00	**[INV01] Presymptomatic medicine in the context of neurodegenerative disease** **John Hardy**, *UK*
15:00–15:30	**[INV02] *ATXN1* transgenic mice cerebellar transcriptome profiles reveal SCA1 disease progression and protection pathways** **Harry Orr**, *USA*
15:30–16:00	**Coffee break** | *Room: The Plaza Suite*
16:00–16:30	**[INV03] Genetic modifiers in Huntington's disease and other triplet repeat diseases** **Lesley Jones**, *UK*
16:30–17:00	**[INV04] Spread of disease through networks** **Karen Duff**, *USA*
17:00–17:30	Panel discussion

Thursday, October 20, 2016	
08:30–09:30	**Registration** | *Room: The Plaza Suite Foyer*
Room	
09:30–12:00	**Session 2: Environmental Factors, Epidemiology, and Primary Prevention** | *Room: The Ballroom* *Chair: Andy Singleton, USA (TBC)*
09:30–10:00	**[INV05] Deconstructing the biological complexity of Alzheimer's disease: implications for therapeutics** **David Bennett**, *USA*
10:00–10:30	**[INV06] Primary prevention of neurodegenerative diseases at the population level** **Kristine Yaffe**, *USA*
10:30–11:00	**Coffee break** | *Room: The Plaza Suite*
11:00–11:30	**[INV07] Genetics to identify presymptomatic Parkinson's disease** **Andy Singleton**, *USA*
11:30–12:00	Panel discussion
12:00–13:00	**Lunch sponsored by Teva Pharmaceuticals** | *Room: The Plaza Suite*
13:00–14:00	**Poster session:** | *Room: The Plaza Suite*
Room	
14:00–17:00	**Session 3: Biomarkers and Early Diagnosis** | *Room: The Ballroom* *Chair: Jonathan Rohrer, UK*
14:00–14:30	**[INV08] Fluid biomarkers in neurodegenerative disease** **Henrik Zetterberg**, *Sweden and UK*
14:30–15:00	**[INV09] Biomarkers and early diagnosis of Alzheimer's disease** **John Morris**, *USA*
15:00–15:30	**Coffee break** | *Room: The Plaza Suite*
15:30–16:00	**[INV10] Biomarkers and early diagnosis of frontotemporal dementia-the GENFI study** **Jonathan Rohrer**, *UK*
16:00–16:30	**[INV11] Biomarkers and early diagnosis of Parkinson's disease** **Alex Iranzo**, *Spain*
16:30–17:00	Panel discussion
17:00–18:00	**Drinks Reception** | *Room: The Plaza Suite*

Friday, October 21, 2016	
Room	
08:30–09:00	**[INV12] A patient's experience** **Jeff Carroll,** *USA*
09:00–12:30	**Session 4: Prevention Through Therapeutics** | *Room: The Ballroom* *Chair: Sarah Tabrizi, UK*
09:00–09:30	**[INV13] Genome editing and gene–targeted approaches as a therapeutic option for the future** **Geoffrey Nichol,** *USA*
09:30–10:00	**[INV14] Antibody trials in Alzheimer's disease** **Roger Nitsch**, *Switzerland*
10:00–10:30	**Coffee break** | *Room: The Plaza Suite*
10.30–11:00	**[INV15] Gene silencing approaches for Huntington's disease** **Sarah Tabrizi**, *UK*
11.00–11:30	**[INV16] Preclinical Alzheimer's disease trials** **Eric Reiman**, *USA*
11:30–12:00	**[INV17] ALS SOD1 trials** **Merit Cudkowicz**, *USA*
12:00–12:30	Panel discussion
12:30–13:30	**Lunch** | *Room: The Plaza Suite*
13:30–14:00	Poster session | *Room: The Plaza Suite*
14:00–14:10	Poster awards
Room	
14:10–15:40	**Session 5: Trials; Regulatory and Ethical Considerations** | *Room: The Ballroom* *Chair: Nick Fox, UK (TBC)*
14:10–14:40	**[INV18] Enroll-HD: A platform to conduct comprehensive longitudinal clinical studies and trials in pre-manifest HD** **Bernhard Landwehrmeyer**, *Germany*
14:40–15:10	**[INV19] Ethical considerations of presymptomatic therapeutic trials in South America–experience of the Cuban SCA2 cohort** **Luis Velazquez-Perez,** *Cuba*
15:10–15:40	Panel discussion
15:40–16:10	**Coffee break** | *Room: The Plaza Suite*
16:10–17:40	**Discussion with panelists:** **Nick Fox,** *UK* **Maria Isaac,** *UK* **Eric Karran,** *USA* **Cristina Sampaio,** *USA* **Discussion point 1** Does a therapy need to show an effect in a symptomatic cohort before it is trialled in a presymptomatic cohort? **Discussion point 2** Do subjects need to know their risk status to go into the trial? **Discussion point 3** What stage of disease (how early) should one recruit to a prevention trial? **Discussion point 4** Should outcome measures be different for a presymptomatic study? **Discussion point 5** Should members of cohort studies—eg, birth cohorts—be offered inclusion in treatment trials?
17:40–18:00	Closing remarks
18:00–18:05	**End of conference**